Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.
News|Podcasts|October 7, 2026
Laboratory Advantage: End-to-End Solutions for Increased Complexity in Clinical Trials
Laboratory logistics form the foundation of clinical research by ensuring biological samples, investigational materials, and time-sensitive data move safely and seamlessly across sites. Marken UPS Healthcare Precision Logistics offers Laboratory Advantage, a service line that draws on years of expertise to bring accuracy and optimization to trials. In this podcast, hear from Jainisha Patel, Marken’s Senior Director of Alliance Management at Marken, as she talks about the expanded capabilities used to elevate logistics to support the growing complexity in clinical trials worldwide. Through specialized specimen transport, enhanced lab operations, customized kitting solutions, and vial-level visibility, discover how Marken ensures samples remain stable, traceable, and compliant.
Related to this article
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring remains a key consideration.
How the proposed lateral network can change the traditional mindset around communications and pharma’s role in today’s new flow of health information.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Caribou Biosciences is discontinuing its two allogeneic CAR-T programs and exploring strategic alternatives to maximize shareholder value.
What North American and APAC sponsors need to know about EU Joint Clinical Assessment — and why EMA approval doesn't guarantee reimbursement.
CORXEL’s chief medical value discusses how GLP-1s are becoming a chronic disease platform.
Trending on PharmExec
1
Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech
2
Caribou Biosciences Discontinues Development for Vispa-cel & CB-011 CAR-T Cell Therapy Programs
3
What Supply Chain Resilience Actually Requires in a Volatile Global Market: LogiPharma2026
4
MFN Raises the Stakes for Japan Launch Pricing
5